Redmile Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Redmile Group’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,125	Closed	-$321K	–	57
2016 Q2	$321K	Buy	3,125 +1,875	+150%	+$187K	0.03%	48
2016 Q1	$115K	Buy	+1,250	New	+$133K	0.01%	45
2015 Q3	–	Sell	-18,750	Closed	-$3.06M	–	69
2015 Q2	$3.06M	Buy	+18,750	New	+$3.18M	0.25%	50

Other funds holding SIOX

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ZBI

Ziff Brothers Investments New York $267M AUM 49.36% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group's SIOX Position: Q3 2016 in Review

Redmile Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2016, closing a stake of 3,125 shares — an estimated $321K sold.

Redmile Group first reported a position in SIOX in Q2 2015 and held it in 3 quarters. The position peaked at $3.06M in Q2 2015. 95 funds tracked by Wall St. Rank hold SIOX as of Q3 2016.

Redmile Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
Redmile Group sold 3,125 Sio Gene Therapies Inc. Common Stock shares in Q3 2016, an estimated $321K.
Redmile Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 3 quarters.
Redmile Group's Sio Gene Therapies Inc. Common Stock position peaked at $3.06M in Q2 2015.
95 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2016.

Based on Redmile Group's 13F filing for Q3 2016, filed 15 Nov 2016.